pharma · Hemophilia A
Gritgen Therapeutics Co
Gritgen Therapeutics Co.,
Gritgen Therapeutics Co is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hemophilia A. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this en
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
GS1191-0445 injection
Phase 3 · small molecule · Hemophilia A
GS1191-0445 injection for Hemophilia A is a Phase 3 program (small_molecule) at Gritgen Therapeutics Co., with 1 ClinicalTrials.gov record(s).
Internal code GS1191-0445-GTHA-CN02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Gritgen Therapeutics Co.,
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Hemophilia A
- Status
- active
- Trials
- 1